Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.
Anticancer Res. 2014 Feb;34(2):927-31.
The aim of the present study was to evaluate the feasibility of, and compliance with a regimen using split-dose cisplatin and vinorelbine (split-CV) as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC).
The treatment schedule included cisplatin at 40 mg/m(2) and vinorelbine at 25 mg/m(2) administered intravenously on days 1 and 8, every three weeks for four cycles.
This study included 22 patients (male/female; 12/10) with a median age of 67 (range 50-76) years; 10 had clinical stage II and 12 stage III; 21 had ECOG 0 and 1 patient ECOG 1; 15 patients had adenocarcinoma, 5 squamous cell and 2 adenosquamous carcinoma; 18 patients had undergone lobectomy, 3 pneumonectomy and 1 segmentectomy. Seventeen out of 22 patients (77%) received the planned 4 cycles. The main adverse events were grade 3/4 neutropenia (76%) and anemia (12%). The average total doses of cisplatin and vinorelbine were 285 mg/m(2) and 177 mg/m(2), respectively.
The split-CV regimen is well-tolerated as adjuvant chemotherapy for completely resected NSCLC.
本研究旨在评估完全切除的非小细胞肺癌（NSCLC）患者使用顺铂和长春瑞滨（split-CV）分剂量方案作为辅助化疗的可行性和依从性。
治疗方案包括顺铂 40mg/m² 和长春瑞滨 25mg/m²，静脉给药，第 1 天和第 8 天给药，每 3 周为 1 个周期，共 4 个周期。
本研究共纳入 22 例患者（男/女；12/10），中位年龄为 67 岁（范围 50-76 岁）；10 例为临床 II 期，12 例为 III 期；21 例 ECOG 评分为 0，1 例为 ECOG 评分为 1；15 例为腺癌，5 例为鳞癌，2 例为腺鳞癌；18 例患者行肺叶切除术，3 例患者行全肺切除术，1 例患者行肺段切除术。22 例患者中有 17 例（77%）接受了计划的 4 个周期治疗。主要不良反应为 3/4 级中性粒细胞减少（76%）和贫血（12%）。顺铂和长春瑞滨的平均总剂量分别为 285mg/m² 和 177mg/m²。
split-CV 方案作为完全切除的 NSCLC 的辅助化疗方案具有良好的耐受性。
Zotero 插件